• Gan & Lee Celebrates Tenth Anniversary with Biomm

On April 26, the CEO of Gan & Lee Pharmaceuticals, Du Kai, and the business delegation joined Brazilian President Luiz Inácio Lula da Silva, Health Minister Nísia Trindade Lima, and Finance Minister Fernando Haddad at the inauguration ceremony of the insulin factory of Biomm, Gan & Lee Pharmaceuticals' Brazilian partner. This event marked a significant collaboration, featuring both Brazilian officials and representatives from Gan & Lee Pharmaceuticals celebrating together.

On April 26, the President of Brazil, Mr. Luiz Inácio Lula da Silva, attended the inauguration ceremony of the insulin plant of Biomm S.A. (hereinafter referred to as Biomm, which is Gan & Lee Pharmaceuticals' partner in Brazil), together with the Minister of Health, Ms. Nísia Trindade Lima, the Minister of Finance, Mr. Minister Fernando Haddad, and other government officials. At the same time, CEO of Gan & Lee Pharmaceuticals, Mr. Dukai, led the business team to the plant to meet with the President and customers when attending the plant inauguration ceremony. This event marked a significant collaboration, featuring both Brazilian officials and representatives from Gan & Lee Pharmaceuticals celebrating together.

Since 2014, Gan & Lee Pharmaceuticals and Biomm established the collaboration, the two companies have strengthened the communication and formed a deep and close strategic partnership over the past ten years. The new facility of Biomm, situated in Minas Gerais, functions as a production base for insulin. Through a technology transfer from Gan & Lee, Biomm has become the first local company capable of manufacturing insulin. In April of this year, the plant received approval from ANVISA ((Agência Nacional de Vigilância Sanitária), Brazil's health regulatory agency, and is now ready to begin production.

The completion of this plant symbolizes the deep cooperation between China and Brazil in the field of pharmaceuticals and high technology. As it is the 50th anniversary of the establishment of diplomatic relations between China and Brazil, this ceremony also contributes Gan & Lee's strength to the beautiful friendship between the two countries, which has a long history.

According to the International Diabetes Federation (IDF) Atlas, 10th edition (2021), Brazil has the highest number of people with diabetes in Latin America, with approximately 15.7 million individuals aged 20 to 79. This accounts for 47.5% of the region's total diabetic population. Against this backdrop, the opening of the new Biomm factory marks a significant milestone. This facility not only achieves a breakthrough in local insulin production but also substantially reduces treatment costs for Brazilian diabetes patients. By enhancing the accessibility and stability of insulin supply, the factory promises to deliver substantial social and economic benefits to local patients and healthcare system.

For many years, Gan & Lee Pharmaceuticals has been dedicated to expanding its international presence, consistently focusing on registering and launching its products in international markets. Brazil, in particular, has been a key strategic location for these efforts. In 2020, Gan & Lee made its first commercial shipment of Glargilin® to Biomm. By 2024, Biomm had successfully achieved local filling and packaging of this product.

Currently, a range of Gan & Lee products, including glargine cartridges and pre-filled pens, and reusable pens, have been progressively approved and launched in Brazil. Gan & Lee Pharmaceuticals is dedicated to addressing the unmet clinical needs of diabetes patients by providing safe, effective, and affordable products. Additionally, the company is committed to transferring high-barrier insulin production technology to Brazil through its partnership with Biomm, continuously driving the development of Brazil's pharmaceutical industry.

This year marks the tenth anniversary of the strategic partnership between Biomm and Gan & Lee Pharmaceuticals. To celebrate this milestone, Du Kai, CEO of Gan & Lee Pharmaceuticals, presented a commemorative 10th-anniversary gift to Heraldo, CEO of Biomm, highlighting the deepened cooperation and mutual success of both parties.

Gan & Lee Pharmaceuticals, a leading biopharmaceutical company in China, specializes in developing and exporting insulin analogs. The company has successfully registered and launched its products in more than 20 countries worldwide. Moving forward, Gan & Lee is committed to expanding its comprehensive portfolio of diabetes therapeutics. Through various collaborative efforts, the company aims to enhance patient care globally by delivering higher-quality products and services.

Reference：

International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.